factual

Two-thirds of cancer approvals rest on weak endpoints

Of 100 consecutive oncology drug approvals, only about a third improve overall survival or quality of life; a third merely delay progression-free survival, which only gives the illusion of being meaningful because it rests on arbitrary radiographic cut-offs; and a third are approved on single-arm studies with no control arm using response rate—so approving drugs on these surrogate endpoints means many likely do not improve survival or quality of life.

factualpending

Speaker

Vinay Prasad

Evidence Quote

“by approving drugs based on these endpoints, it is likely that many of them simply don't improve survival and don't improve quality of life”

Source

Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant— EconTalk
Created: 6/13/2026, 12:28:36 AM

Your notes

Loading notes...